Werner J Geldenhuys

US Patent:

20090143457, Jun 4, 2009

Filed:

Dec 4, 2008

Appl. No.:

12/328238

Inventors:

Cornelis J. Van der Schyf - Akron OH, US
Randolph B. Schiffer - Lubbock TX, US
Paula Grammas - Lubbock TX, US
Masao Roy Wilson - Denver CO, US
Werner J. Geldenhuys - Kent OH, US

Assignee:

NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE - Rootstown OH

International Classification:

C07D 209/56
A61K 31/403
A61P 27/02

US Classification:

514410, 548420

Abstract:

Described herein are various compounds for treatment of ocular neurodegenerative diseases, including but not limited to glaucoma and diabetic retinopathy. The compounds described herein can act to attenuate and/or block calcium release from external neuronal environments as well as intracellular stores.

US Patent:

20190388381, Dec 26, 2019

Filed:

Jun 21, 2019

Appl. No.:

16/448312

Inventors:

Mary E. Konkle - Muncie IN, US
Michael A. Menze - Louisville KY, US
Werner J. Geldenhuys - Morgantown WV, US

International Classification:

A61K 31/341

Abstract:

Methods of inhibiting formation of complexes of CDGSH iron-sulfur domain (CISD) protein and pyridoxal-5′-phosphate (PLP) are provided herein. More specifically, methods of inhibiting formation of CISD protein-PLP complexes include exposing a CISD protein to a compound with specific binding affinity for a designated lysine residue in the CISD protein. Inhibition of CISD protein-PLP complex formation is relevant to disease states associated with the CISD protein-PLP complex.

US Patent:

20140271903, Sep 18, 2014

Filed:

Mar 14, 2013

Appl. No.:

13/803585

Inventors:

- Rootstown OH, US
Hiroshi Nakamura - Hudson OH, US
Werner Geldenhuys - Kent OH, US

International Classification:

A61K 47/34
A61K 9/51
A61K 31/4439

US Classification:

424501, 5147721

Abstract:

The present invention relates to a methods for extending the period of filtering bleb survival and/or providing for long term bleb survival following Glaucoma Filtration Surgery by delivering an ALK-5 inhibitor to a wound area (the surgical site) of a patient's eye. More particularly, the present invention relates to a method for the controlled delivery of an ALK-5 inhibitor to patient's eye using a thermo-sensitive polymer formulation, wherein the ALK-5 inhibitor is first contained in the polymer formulation at a temperature sufficient to maintain the formulation as a liquid and then applied to the eye wound opening, wherein the formulation turns to a gel. The use of the thermo-sensitive gel with ALK-5 inhibitor contained therein, provides for longer term bleb survival following Glaucoma Filtration Surgery (GFS) on a patient's eye. Thus, the present invention is particularly effective in inhibiting ocular fibrotic wound response following GFS.